Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Diseases and Conditions Researched

Cystic Fibrosis

What is the purpose of this trial?

This is a point prevalence study conducted entirely in the United States (US) to establish the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT) for pancreatic insufficiency compared with matched (age and region of residence) control patients unexposed to PERT.

Participation Guidelines

Age: 2 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: AbbVie Inc.
Last Updated:
Study HIC#: 1311013023